This pathomechanism can be translated into humans, as leukocytes isolated from CKD patients show increased rolling velocity which can be reduced by pharmacologic FGFR inhibition, and vice versa, FGF23 treatment of leukocytes isolated from healthy subjects elevates rolling velocity (241). Here, FGF23 is linked to chronic kidney disease.